Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:57:16.772Z.
Consensus retrieved: 2026-10-06T12:46:50.469Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:57:16.772Z.
Quote observation: 2026-10-06T19:55:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dfad1c05cc2aa8f6cb068a9889f655595699d907bef32c8b30a8328fbc25ce63
Forward PE Ratio (N/A) = Dated Quote Price ($5.79) / Consensus Forward EPS ($-0.76)
FORWARD PE RATIO
N/A
Inogen, Inc.
Market Cap
$156.68M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Inogen, Inc. (INGN) | $156.68M | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $158.14M | N/A |
| PepGen Inc. (PEPG)vs › | $158.74M | N/A |
| Neuronetics, Inc. (STIM)vs › | $154.32M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $159.91M | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $161.43M | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $151.31M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | N/A |
| Quanterix Corporation (QTRX)vs › | $162.52M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $5.79, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.76 | $-0.77 – $-0.76 | 1 | n/m |
| 2027-12-31 | $-0.48 | $-0.48 – $-0.47 | 1 | n/m |
| 2028-12-31 | $-0.27 | $-0.41 – $-0.13 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
